Taking weight loss drugs is no longer the road less traveled, and people are going over 1,000 miles to get their hands on ...
Thomas Oxley, CEO of Synchron Inc., a rival to Elon Musk's Neuralink, said the company is preparing to recruit patients for a ...
Gabe "Gaben" Newell, the man behind Steam, has for years been quietly building a BCI company — and it just came out of ...
An Akebia Therapeutics drug for a type of anemia has won FDA approval, a regulatory decision ... of high altitude on the body, these drugs get the body to produce erythropoietin.
Opsynvi, a Single-Tablet Combo Therapy for PAH, Gets FDA Approval Praluent (alirocumab) Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor As an adjunct to diet and other low density ...
Synchron has thus far implanted its chip in 10 patients (six in the US and four in Australia) and has seen them gain the ...
A psychoactive drug crafted from human bones is leaving addicts in the West African country of Sierra Leone digging up graves in order to get their fix. According to the BBC, this haunting menace ...
The Food and Drug Administration (FDA) approved the gene therapy Casgevy in December, which uses CRISPR/Cas9 genome editing technology to treat sickle-cell disease (SCD) in patients twelve years ...
Washington: Synchron Inc, a rival to Elon Musk's Neuralink brain implant startup ... No company has received final FDA approval to market a BCI brain implant. Synchron's device is delivered ...
Synchron Inc, a rival to Elon Musk's Neuralink brain implant startup ... No company has received final FDA approval to market a BCI brain implant. Synchron's device is delivered to the brain ...
With accelerated approval, patients get access to drugs earlier, but the tradeoff means some of the medications don't pan out. It's up to the FDA or the drugmaker to withdraw disappointing drugs ...
The U.S. Food and Drug Administration ... before gaining full approval. Read More: Why Are So Many Young People Getting Cancer? It’s Complicated Patients get access to drugs earlier, but ...